Health Care Fund
Daily price w/o sales charge as of 02/27/2020
$15.36
$0.42
YTD Returns w/o sales charge as of 02/27/2020
-5.24%
Please click here for performance current to the most recent quarter-end and month-end.
Summary
Summary
The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of companies within the health care sector.
Fund Basicsas of 01/31/2020
- Total Net Assets
- $3.51 M
- Inception Date
- 08/01/2019
- Dividend Frequency
- Monthly (Daily Accrual)
- Fund Gross Expense Ratio
- 8.85%
- Fund Net Expense Ratio
- 0.78%
- Number of Holdings
- 81
Fund Expense Ratio :
Gross 8.85%
Net 0.78%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | -1.60% | - | - | - | - | 6.34% |
| Lipper Category Avg. Health/Biotechnology Funds | -2.98% | - | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | -1.42% | - | - | - | - | 11.82% |
Fund Expense Ratio :
Gross 8.85%
Net 0.78%
Fund Expense Ratio :
Gross 8.85%
Net 0.78%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | - | - | - | - | - | 8.07% |
| Lipper Category Avg. Health/Biotechnology Funds | - | - | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | - | - | - | - | - | 13.43% |
Performance data for the Lipper Category Average and for the Index is shown as soon as it becomes available.
Fund Expense Ratio :
Gross 8.85%
Net 0.78%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
Returns with sales charge reflect a maximum sales charge of 5.75%
INVESTMENT TEAM
Contact a Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
Gross 8.85%
Net 0.78%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | -1.60% | - | - | - | - | 6.34% |
| Lipper Category Avg. Health/Biotechnology Funds | -2.98% | - | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | -1.42% | - | - | - | - | 11.82% |
Fund Expense Ratio :
Gross 8.85%
Net 0.78%
Fund Expense Ratio :
Gross 8.85%
Net 0.78%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | - | - | - | - | - | 8.07% |
| Lipper Category Avg. Health/Biotechnology Funds | - | - | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | - | - | - | - | - | 13.43% |
Performance data for the Lipper Category Average and for the Index is shown as soon as it becomes available.
Fund Expense Ratio :
Gross 8.85%
Net 0.78%
NAV Historical Prices
| Date | Net Asset Value |
|---|
Portfolio
Portfolio
Portfolio Details as of 01/31/2020
- Total Net Assets
- $3.51 M
- Number of Holdings
- 81
- Weighted Average Market Cap.
- 68.1 B
- P/B Ratio
- 5.7x
- P/E Ratio
- 32.9x
To view definitions for the above Portfolio Details, Click here.
| Holding | Sector | Assets |
|---|
| Merck & Co., Inc. | Health Care | 4.2% |
| Novartis AG Registered Shares | Health Care | 3.9% |
| Abbott Laboratories | Health Care | 3.8% |
| AstraZeneca plc | Health Care | 3.6% |
| Vertex Pharmaceuticals, Inc. | Health Care | 3.3% |
| Zoetis, Inc. | Health Care | 2.7% |
| Novo Nordisk A/S | Health Care | 2.6% |
| CVS Caremark Corp. | Health Care | 2.5% |
| Amgen, Inc. | Health Care | 2.5% |
| Danaher Corp. | Health Care | 2.5% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
| Holding | Sector | Assets |
|---|
| Merck & Co., Inc. | Health Care | 4.3% |
| Novartis AG Registered Shares | Health Care | 4.2% |
| Abbott Laboratories | Health Care | 3.6% |
| AstraZeneca plc | Health Care | 3.5% |
| Vertex Pharmaceuticals, Inc. | Health Care | 3.1% |
| Amgen, Inc. | Health Care | 2.7% |
| CVS Caremark Corp. | Health Care | 2.7% |
| Zoetis, Inc. | Health Care | 2.6% |
| Johnson & Johnson, Inc. | Health Care | 2.5% |
| Intuitive Surgical, Inc. | Health Care | 2.4% |
| Danaher Corp. | Health Care | 2.3% |
| Novo Nordisk A/S | Health Care | 1.9% |
| Boston Scientific Corp. | Health Care | 1.9% |
| Thermo Fisher Scientific, Inc. | Health Care | 1.9% |
| Stryker Corp. | Health Care | 1.8% |
| Zimmer Biomet Holdings, Inc. | Health Care | 1.8% |
| Edwards Lifesciences Corp. | Health Care | 1.6% |
| Centene Corp. | Health Care | 1.5% |
| UnitedHealth Group, Inc. | Health Care | 1.4% |
| Genmab A/S | Health Care | 1.4% |
| Teleflex, Inc. | Health Care | 1.4% |
| Lonza Group AG | Health Care | 1.3% |
| Nevro Corp. | Health Care | 1.3% |
| Seattle Genetics, Inc. | Health Care | 1.2% |
| DexCom, Inc. | Health Care | 1.2% |
| Mirati Therapeutics, Inc. | Health Care | 1.2% |
| Repligen Corp. | Health Care | 1.2% |
| uniQure NV | Health Care | 1.2% |
| Insulet Corp. | Health Care | 1.1% |
| Cooper Cos., Inc. | Health Care | 1.1% |
| HCA Holdings, Inc. | Health Care | 1.1% |
| Align Technology, Inc. | Health Care | 1.1% |
| Bio-Rad Laboratories, Inc. | Health Care | 1.1% |
| ArQule Inc | Health Care | 1.0% |
| Veeva Systems, Inc. | Technology | 1.0% |
| Illumina, Inc. | Health Care | 1.0% |
| Anthem, Inc. | Health Care | 1.0% |
| Argenx SE | Health Care | 1.0% |
| Neurocrine Biosciences, Inc. | Health Care | 1.0% |
| Charles River Laboratories International, Inc. | Health Care | 1.0% |
| Natera, Inc. | Health Care | 1.0% |
| Bridgebio Pharma Inc | Health Care | 0.9% |
| ACADIA Pharmaceuticals, Inc. | Health Care | 0.9% |
| LivaNova PLC | Health Care | 0.9% |
| Turning Point Therapeutics Inc | Health Care | 0.9% |
| 10X Genomics Inc | Health Care | 0.9% |
| Codexis Inc | Materials and Processing | 0.9% |
| IDEXX Laboratories, Inc. | Health Care | 0.8% |
| Sarepta Therapeutics, Inc. | Health Care | 0.8% |
| Tandem Diabetes Care, Inc. | Health Care | 0.8% |
| Blueprint Medicines Corp. | Health Care | 0.8% |
| Penumbra, Inc. | Health Care | 0.8% |
| Twist Bioscience Corp | Health Care | 0.8% |
| Natus Medical, Inc. | Health Care | 0.7% |
| Agilent Technologies, Inc. | Technology | 0.7% |
| eHealth, Inc. | Financial Services | 0.7% |
| ChemoCentryx Inc | Health Care | 0.7% |
| Coherus Biosciences, Inc. | Health Care | 0.7% |
| Karuna Therapeutics Inc | Health Care | 0.7% |
| NextCure Inc | Health Care | 0.7% |
| HealthEquity, Inc. | Financial Services | 0.7% |
| Forty Seven Inc | Health Care | 0.7% |
| Silk Road Medical Inc | Health Care | 0.7% |
| Teladoc Health | Health Care | 0.6% |
| DENTSPLY International, Inc. | Health Care | 0.6% |
| Rocket Pharmaceuticals Inc | Health Care | 0.6% |
| Morphosys AG | Health Care | 0.6% |
| Amarin Corp. plc | Health Care | 0.6% |
| Phreesia Inc | Technology | 0.6% |
| Insmed, Inc. | Health Care | 0.6% |
| MyoKardia Inc | Health Care | 0.6% |
| GW Pharmaceuticals plc | Health Care | 0.5% |
| Quotient Ltd | Health Care | 0.5% |
| Glaukos Corp. | Health Care | 0.5% |
| Krystal Biotech Inc | Health Care | 0.5% |
| Guardant Health Inc | Health Care | 0.4% |
| Techne Corp. | Health Care | 0.4% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Attribution Analysis
| Health Care Fund | Benchmark | Variance | |||||
|---|---|---|---|---|---|---|---|
| Sector | Avg. Weight | Base Return | Avg. Weight | Base Return | Stock Selection | Group Weight | Total |
The total base return displayed for the Fund does not capture daily cash flow and trading activity and therefore is subject to reasonable variance from the Fund's actual return. Please refer to Lord Abbett International Core Fund Performance Results for the Fund's longer-term returns. The Fund is actively managed and portfolio characteristics, such as individual holdings and sector weightings, may change significantly over time.
Source: Wilshire Attribution Software. GICS sector classification; non-GICS securities classified by Lord Abbett. Sectors may include many industries.
Contributors & Detractors as of 12/31/2019
Contributors
| Holding | Contribution |
|---|---|
| Vertex Pharmaceutica | 1.0% |
| Arqule Inc. | 0.8% |
| Nextcure Inc | 0.7% |
| Uniqure Nv | 0.7% |
| Mirati Therapeutics Inc | 0.6% |
Detractors
| Holding | Contribution |
|---|---|
| Sage Therapeutics Inc | -0.2% |
| Karuna Therapeutics Inc | -0.2% |
| Twist Bioscience Corp | -0.2% |
| Stryker Corp. | -0.1% |
| Veeva Systems, Inc. | -0.1% |
Fees & Expenses
Fees & Expenses
Expense Ratioas of 01/31/2020
| Fund Gross Expense Ratio | Fund Net Expense Ratio | |
|---|---|---|
| 8.85% | 0.78% |
Expense ratio details, Click here.
The net expense ratio takes into account contractual fee waivers/expense reimbursements that currently are scheduled to remain in place through 02/28/2021. For periods when fees and expenses were waived and/or reimbursed, the Fund benefited by not bearing such expenses. Without such fee waivers/reimbursements, performance would have been lower.
Fund Documents
Fund Documents
Download fund documents & literature, create email subscriptions, and place direct mail order
|
0Documents selected
|
Order | ||||
|---|---|---|---|---|---|
|
Summary Prospectus
Publish Date:11/03/2015
|
|||||
| n/a |
Statutory Prospectus
Publish Date:11/03/2015
|
||||
| n/a |
Prospectus (XBRL)
Publish Date:11/03/2015
|
||||
|
SAI
Publish Date:11/03/2015
|
|||||
|
Fact Sheet
Publish Date:11/03/2015
|
|||||
|
Commentary
Publish Date:11/03/2015
|
|||||